A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Bristol-Myers Squibb
Amgen
NuCana plc
Akeso
GlaxoSmithKline
OncoResponse, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Seagen Inc.
University of Jena
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University College, London
Dana-Farber Cancer Institute